Oxford Immunotec Global (NASDAQ:OXFD) received a $20.00 price target from stock analysts at Piper Jaffray Companies in a research note issued on Wednesday, TipRanks reports. The brokerage presently has a “buy” rating on the stock. Piper Jaffray Companies’ price objective indicates a potential upside of 37.46% from the company’s previous close.
OXFD has been the subject of a number of other research reports. Zacks Investment Research cut shares of Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. TheStreet cut shares of Oxford Immunotec Global from a “c-” rating to a “d+” rating in a research report on Monday, July 15th. ValuEngine cut shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Finally, BidaskClub upgraded shares of Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a research report on Friday. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the stock. Oxford Immunotec Global currently has a consensus rating of “Hold” and an average target price of $19.00.
OXFD traded up $0.43 during midday trading on Wednesday, reaching $14.55. 151,916 shares of the company’s stock were exchanged, compared to its average volume of 168,589. The company has a debt-to-equity ratio of 0.03, a current ratio of 13.35 and a quick ratio of 12.76. The stock has a market capitalization of $378.31 million, a PE ratio of 28.53 and a beta of 0.37. The business’s 50-day moving average price is $13.64 and its 200 day moving average price is $14.84. Oxford Immunotec Global has a 1-year low of $11.88 and a 1-year high of $19.19.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.07. The company had revenue of $19.60 million during the quarter, compared to analysts’ expectations of $19.32 million. Oxford Immunotec Global had a net margin of 208.48% and a return on equity of 14.76%. The firm’s quarterly revenue was up 17.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.25) earnings per share. As a group, analysts expect that Oxford Immunotec Global will post -0.17 EPS for the current fiscal year.
In other news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $19.90, for a total transaction of $59,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Peter Wrighton-Smith sold 10,000 shares of Oxford Immunotec Global stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $13.86, for a total transaction of $138,600.00. Following the sale, the chief executive officer now owns 424,538 shares of the company’s stock, valued at $5,884,096.68. The disclosure for this sale can be found here. Insiders own 4.21% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of OXFD. River & Mercantile Asset Management LLP purchased a new stake in Oxford Immunotec Global in the second quarter valued at approximately $1,980,000. Susquehanna International Group LLP purchased a new stake in Oxford Immunotec Global in the second quarter valued at approximately $162,000. Zacks Investment Management purchased a new stake in Oxford Immunotec Global in the second quarter valued at approximately $345,000. Jane Street Group LLC purchased a new stake in Oxford Immunotec Global in the second quarter valued at approximately $557,000. Finally, Citadel Advisors LLC grew its holdings in Oxford Immunotec Global by 269.5% in the second quarter. Citadel Advisors LLC now owns 326,304 shares of the company’s stock valued at $4,490,000 after purchasing an additional 238,001 shares during the period. Institutional investors and hedge funds own 94.09% of the company’s stock.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Read More: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.